Background: Although most patients with gestational trophoblastic neoplasia (GTN) are cured by conventional chemotherapy, some develop drug resistance or relapse. The use of new combination drugs has been studied to treat those with resistant or relapsed disease. We evaluated the results of floxuridine, dactinomycin, etoposide, and vincristine (FAEV) chemotherapy in patients with relapsed/chemoresistant GTN.
introduction
Due to the introduction of effective chemotherapy, the ability to monitor treatment progress with human serum b-human chorionic gonadotrophin (b-hCG) levels and the individualized chemotherapy based on prognostic factors, gestational trophoblastic neoplasia (GTN) has become a highly curable tumor. At present, ‡90% of patients with GTN are cured with chemotherapy due to the inherent chemosensitivity of this disease; a minority of patients have an incomplete response to chemotherapy, or relapse after the completion of initial treatment [1] [2] [3] [4] .
In Britain and the United States, women with high-risk GTN are usually treated with primary combination chemotherapy with etoposide, methotrexate, and dactinomycin, alternating with cyclophosphamide and vincristine (EMA-CO) [5] [6] [7] .
Patients with disease resistant to EMA-CO may be treated by etoposide, methotrexate, and dactinomycin, alternating with etoposide and cisplatin (EMA-EP) or platinum-based combination chemotherapy [8] . Recently, Wang et al. [1] from Charing Cross Hospital reported that a novel three-drug doublet regimen consisting of paclitaxel, cisplatin, and etoposide (TP/TE) induced response rate in 8 (50%) of 16 patients with relapsed or refractory GTN. However, in China, 5-fluorouracil (5-FU) is the single-agent chemotherapy used most frequently, 5-FU, dactinomycin, vincristine (FAV) is the preferred combined chemotherapy, and EMA-CO is also commonly used as a combination chemotherapy in some regional centers [9] [10] [11] [12] .
As the largest GTN center in China, the Peking Union Medical College Hospital (PUMCH) often admits patients with GTN after treatment elsewhere, particularly those who have become chemoresistant or have relapsed after failure of treatment elsewhere. In view of our experience with chemotherapy for GTN, our preference is to use FAV regimen for patients with high-risk GTN, although EMA-CO is the most commonly used chemotherapy regimen in other centers of the world. In selecting agents for combination chemotherapy, one of the accepted guidelines is to choose agents that have a different mechanism of action and which have a nonoverlapping mechanism of resistance. Etoposide is a useful anticancer agent, it has a favorable toxicity profile and different mechanism of action to 5-FU and dactinomycin. Moreover, etoposide is included in available chemotherapy regimens for refractory GTN in vast literatures [1, [4] [5] [6] [7] [8] . Therefore, etoposide-containing polychemotherapy was the most commonly used as salvage combination chemotherapy in our previous studies.
Several reports indicate that floxuridine (FUDR) is more effective and less toxic than 5-FU [13] [14] [15] . Therefore, from 2000, FUDR-containing chemotherapy is administered in patients with GTN at the PUMCH. Our earlier report on floxuridine, dactinomycin, etoposide, and vincristine (FAEV) demonstrated a 63.6% of serologic complete remission (SCR) in a population of 11 patients with GTN who were referred to PUMCH because of previous failure of chemotherapy between October 2001 and May 2004 [16] . The goal of the present study is further to determine the efficacy and toxicity of FAEV in patients with relapsed or chemoresistant GTN. However, placental site trophoblastic tumor (PSTT) should be excluded from this analysis because PSTT is curable by surgery when localized and relatively resistant to chemotherapy.
patients and methods patients
We retrospectively reviewed patients with GTN treated with FAEV chemotherapy between 1 January 2005 and 30 June 2008. Patients were identified through review of institutional databases. All patients received FAEV chemotherapy with at least one cycle. Only patients with relapsed or chemoresistant GTN were included in the investigation. Patients were classified according to the reasons for referral: as chemoresistant GTN if they had a plateau (<50% fall in the b-hCG levels) or an increased b-hCG level and/or development of new metastases for at least two consecutive cycles of combined chemotherapy, and relapsed GTN if they had two elevated serum b-hCG levels in the absence of a pregnancy after achieving a minimum of 4 weeks of normal b-hCG values with treatment. Potential cases were excluded if PSTT was pathologically confirmed. All patients provided written informed consent before starting of the treatment and had an Eastern Cooperative Oncology Group performance status between 0 and 2. This study was approved by the Institutional Review Board of PUMCH.
treatment plan
The FAEV regimen was administered as follows: vincristine 2 mg administered by bolus intravenously 3 h before treatment with dactinomycin on day 1; dactinomycin 200 lg/m 2 administered by infusion more than 30 min daily on days 1-5; etoposide 100 mg/m 2 administered by infusion more than 30 min daily on days 1-5; and FUDR 800 mg/m 2 administered by infusion more than 8 h daily on days 1-5. Chemotherapy was recycled in 21-day intervals. Patients discontinued therapy if they had three additional courses of consolidation chemotherapy after normalization of the b-hCG level, a plateau or an increased b-hCG level for at least two consecutive cycles, recurrent grade 3 or 4 toxicity, and any subjectively intolerable toxicity. Standard anti-emetic medication 30 min before chemotherapy daily on days 1-5 was administered. Prophylactic administration of granulocyte colony-stimulating factor (G-CSF) was not done. When neutrophil count was <1.0 · 10 9 /l at routine checkup, G-CSF was administered at the discretion of the treating physician. Neutropenic fever was routinely treated with empiric, broad-spectrum antibiotics. Retreatment with the subsequent cycle required a neutrophil count of ‡2.0 · 10 9 /l, a platelet count of ‡75 · 10 9 /l, hemoglobin level of ‡ 80 g/l, and serum aspartate aminotransferase/ alanine aminotransferase (ALT) £ 1.5· the upper limit of normal. After recovery of toxicity, full-dose chemotherapy was administrated on the day of therapy. Dose reductions were not made, but a change of chemotherapy regimen was carried out in the following conditions: if blood counts and liver function had not recovered to the aforementioned figures on the day of therapy; if grade 4 neutropenia was complicated by fever or infection, or it lasted for 7 days or longer, irrespectively of G-CSF addition; if grade 3 or 4 thrombocytopenia lasted 7 days or longer; or if grade 3 or 4 nonhematologic toxicity, which excluded alopecia, occurred.
adjuvant surgical management
Surgery was used in selected patients with limited resistant or persistent disease. Before deciding to perform surgical resection, computed tomography or magnetic resonance imaging of the brain, chest, abdomen, and ultrasonograpy of the pelvis was carried out to document the presence of uterine disease or disease elsewhere. If there was no evidence of distant metastasis, hysterectomy or hysterotomy for excision of lesion in the uterus was carried out, based on a desire to maintain fertility. If the disease was isolated in distant metastasis sites and there was no evidence of active tumor at other sites, surgical extirpation of metastatic disease was carried out.
efficacy assessment
Patients were assessed for efficacy if they received greater than or equal to two cycles of treatment. Responses were determined through serial serum b-hCG level measurements weekly. A comprehensive evaluation had to be carried out once normal serum b-hCG levels (<2 IU/L) were attained. SCR was defined as normal serum b-hCG levels on at least four consecutive weekly determinations. A partial remission (PR) was defined as a >50% decrease in serum b-hCG levels as compared with the pretreatment value. No response (NR) was defined as a £50% decrease in serum b-hCG levels compared with the pretreatment value or an increase in the serum b-hCG level that continued for at least two consecutive cycles of chemotherapy. After the completion of treatment, serum b-hCG level was measured weekly for 4 weeks, then monthly measurement in the first year, every 3 months in the second year, and every 6 months to 1 year for lifelong.
safety assessment
All patients who received greater than or equal to one cycle of FAEV chemotherapy were eligible for the toxicity assessment. Hematologic and nonhematologic toxicity was assessed through review of laboratory reports and medical records. Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Event, version 3.0.
statistical analysis
The primary objective was measurement of the overall response rate (ORR), including SCR and PR. The secondary objectives were assessment of toxicity and assessment of clinical predictors of response.
Demographic and baseline characteristics were summarized by using medians (with ranges) for continuous variables and proportions for categorical variables. Univariate analysis of the correlations between clinical response and clinical factors was done using the chi-square test. In order to identify independent factors associated with response to FAEV, a multiple logistic regression model was used to control for the same variables tested in the univariate analysis. Multivariate models were constructed using Patient characteristics after referral to the PUMCH are presented in Table 1 . Records of previous chemotherapy or surgical treatments either in other hospitals or at the PUMCH before starting to receive FAEV chemotherapy are presented in Table 2 . At the time of treatment with FAEV, 78% of the subjects had metastatic GTN, the most common metastatic site was lung, found in 69 (76%) women. All patients were heavily pretreated with either chemotherapy alone (n = 68) or combined chemotherapy and surgery (n = 23), 83.5% of patients received at least a prior FU/FUDR-containing polychemotherapy regimen, and 47.3% of patients received prior etoposide-containing polychemotherapy regimen. The median number of prior regimens was 2 and ranged from 1 to 7, 68.1% of patients received at least two prior chemotherapy regimens. Eighty (88%) of the patients had a high-risk GTN.
safety and tolerability
Four hundred and twenty-one cycles of chemotherapy were administered, and all 91 patients were on treatment of a median of five cycles (range 2-11 cycles). Table 3 lists adverse events that occurred during the treatment. The most common adverse events encountered were nausea (59.3%), anemia (53.8%), fatigue (50.5%), neutropenia (48.4%), and anorexia (45.1%). The majority of these episodes were categorized as grade 1 or 2. There were 24 patients of greater than or equal to grade 3 neutropenia, 6 patients of febrile neutropenia, and 3 patients of greater than or equal to grade 3 thrombocytopenia. However, the majority of these greater than or equal to grade 3 hematologic toxicity were transient. Moreover, there were no neutropenic sepsis episodes. Other specific toxic effects included vomit, diarrhea, abnormal ALT, mucositis of oral cavity, rash, sinus tachycardia, and keratitis. No deaths were recorded during treatment. Seven of the patients who developed above mentioned toxic effects discontinued FAEV therapy.
efficacy and predictive factors for response
All 91 patients were assessable for response. Causes for FAEV treatment discontinuation were SCR (55 patients, 60.4%), NR (29 patients, 31.9%), and toxicity (7 patients, 7.7%). Of the 55 SCR patients, 23 (41.8%) patients had adjuvant surgery (15 hysterectomy and 8 thoracotomy), 51 patients achieved durable SCR, and 4 patients had relapsed disease and ultimately died of GTN. Of 29 patients with NR, 15 patients achieved durable SCR by further salvage chemotherapy or combined with surgery (6 hysterectomy, 3 thoracotomy, 1 nephrectomy, and 1 resection of vaginal metastasis), 14 patients progressed and died of GTN, even though the serum b-hCG level was temporarily normalized in 4 of these patients. Of seven patients with toxicity, six patients achieved durable SCR by further salvage chemotherapy or combined hysterectomy (n = 2).
Overall, at the time of analysis, 19 (20.9%) patients died of GTN at the median follow-up of 24 months (9-54 months); 36 of 72 survivors had adjuvant surgery. The survival rate at 3 years after stopping treatment was 74.9% ( Figure 1 ). original article
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Univariate analyses of clinical factors showed that type of antecedent pregnancy, number of previous chemotherapy cycles, number of previous chemotherapy regimens, previous surgery, and previous etoposide-containing polychemotherapy were significantly associated with response to FAEV (Table 4) . However, in multivariate analysis, only number of previous chemotherapy regimens remained significantly associated with SCR (P = 0.041; OR = 7.06, 95% CI 1.08-46.02) ( Table 4 ). ROC analysis showed that a cutoff point of two previous chemotherapy regimens could differentiate between patients' probability of SCR (£2) and NR (>2) with 78% sensitivity and 62% specificity, and with a positive predictive value of 80% and a negative predictive value of 60%. For those who had more than two previous chemotherapy regimens, only 40% achieved SCR, whereas those with two or less previous chemotherapy regimens, 79.6% achieved SCR (P = 0.000).
discussion
Although most patients with GTN are cured by conventional chemotherapy and surgery, some suffer drug resistance or relapse and may die. Managing chemoresistant or relapsed GTN remains a clinical challenge. Several chemotherapy regimens have been used successfully to treat GTN, but the optimum regimen for chemoresistant or relapsed GTN is unknown. In China, the majority of patients with GTN are treated in referral hospitals and not in one central specialized institution. To date, there is no national registry system for GTD, many factors make the initial treatment of GTN different, including affordability of drugs, inadequacy and unavailability of the b-hCG test, and a lack in the use of International Federation of Gynecology and Obstetrics scoring system in some hospitals. Additional, although in our previous study we reported the patients with chemoresistant or relapsed GTN had a different prognosis, they received similar treatment after referral to the PUMCH [17] . Therefore, to evaluate the efficacy of treatment protocols, it was appropriate for chemoresistant or relapsed patients to be mixed due to the rarity of the disease. original article
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Our previous study suggested that FAEV regimen was beneficial in 11 high-risk drug-resistant patients with GTN; the major restrictive adverse event of FAEV regimen was hematologic toxicity [16, 18] . In our current series, 91 patients were treated with this salvage therapy because their disease was either chemoresistant or had relapsed to previous therapies. The regimen was tolerated well, despite the majority of patients were heavily pretreated. As expected, hematological toxicity was the main toxicity; grade 3 or 4 neutropenia, febrile neutropenia, and thrombocytopenia occurred in 26.4%, 6.6%, and 3.3% of patients, respectively. The frequency of hematologic toxicity observed in this study was similar to that observed in our previous small series [16, 18] . Similar findings also emerged in another study for patients with refractory, high-risk GTN, which reported grade 3 or 4 leukocytopenia and thrombocytopenia in 19.2% and 14.1% of patients with FA (5-FU and Actinomycin D) regimens [22] . Although 6.6% of patients experienced febrile neutropenia, none of the patients receiving FAEV experienced neutropenic sepsis. Although grade ‡3 thrombocytopenia was experienced in 3.3% of the patients, none had clinically significant sequalae. Although 53.8% of patients developed grade 1 or 2 anemia, they were treated easily with supportive treatment including blood transfusion. Other common adverse events to FAEV regimen were nausea and vomiting, which were easily circumvented with the use of standard antiemetics and sometimes in combination with corticosteroids. Thus, the toxic effects of the current FAEV regimen were predictable and manageable; this regimen was discontinued in only 7.7% of patients due to toxicity. Furthermore, although FAEV chemotherapy regimen requires more hospital stay than other salvage regimens such as EMA-EP, the interval (3 weeks) between cycles is longer. Therefore, administration of the FAEV is also convenient.
In the previous studies, several groups reported 74-79% of complete response rate to EMA-CO regimen as the second-or third-line therapy [20, 21] . However, the majority of patients receiving EMA-CO as the second-or third-line therapy were resistant to single-drug therapy [1, 20, 21] . To date, it has been quite difficult to manage high-risk GTN patients resistant to EMA-CO regimen. It was reported that EMA-EP regimen was an appropriate selection for those patients [4, 12] . However, 40% of patients receiving EMA-EP suffered multiple grade 3 or 4 toxic effects, although EMA-EP with or without surgery cured a further 75% of cases who failed EMA-CO [8] . Recently, Wang et al. [1] reported an ORR of 50% to TP/TE in 16 patients with relapsed or refractory GTN who had received a median of 2 (range 1-9) previous therapies, as well as the TP/TE regimen was generally well tolerated. In the present study, we treated 91 chemoresistant or relapsed patients with the FAEV regimen, and got a SCR of 60.4%. The overall outcomes of FAEV chemotherapy for chemoresistant or relapsed GTN in our study appeared to be consistent with those in previous reports [1, 12, [19] [20] [21] . On the other hand, 41.8% (23/55) patients in SCR group and 50% of survivors at final analysis received adjuvant surgery. Thus, adjuvant surgery might improve the remission rate. In our previous study, 61 patients with chemotherapyresistant GTN who underwent surgery achieved 77% of SCR, 6.6% of PR, and 16.4% of NR [22] . Therefore, we would like to emphasize the importance of salvage surgery in this group of patients.
It is widely recognized that there are a series of adverse prognostic variables in terms of survival for patients with highrisk GTN [5, 8, 12] . However, the factors that influence the efficacy of specific chemotherapy regimen are still uncertain. Kim et al. [21] found that the significant factors related to EMA-CO failure were age, number of metastatic organs, metastatic site, and inadequate previous chemotherapy in multivariate analysis using stepwise Cox proportional hazards regression. Escobar et al. [23] found that duration of disease from antecedent pregnancy to treatment and metastatic site significantly influenced the complete response to EMA-CO chemotherapy. However, these studies were limited by the small sample size. In this study, we analyzed the factors associated with SCR to FAEV using univariate and multivariate analysis and found that only the number of previous chemotherapy regimens was an independent factor influencing SCR, though type of antecedent pregnancy, number of previous chemotherapy cycles, previous surgery, and previous etoposidecontaining polychemotherapy were significantly related to the SCR using univariate analysis. In view of the extreme rarity of chemoresistant or relapsed GTN, substantially increased datasets are unlikely to be obtained in the near future. We therefore used both univariate and multivariate analyses despite the obvious limitations of a multivariate outcome analysis from a small dataset. Results are exploratory and should be interpreted with caution. Why an independent factor influencing SCR was less than or equal to two previous chemotherapy regimens is as yet unclear. Logically, patients having less than or equal to two previous chemotherapy regimens could have had less cross-resistance between FAEV and other regimens. Consideration of previous chemotherapy regimens could help to direct the changing of chemotherapy regimens.
In conclusion, the current study confirmed that FAEV regimen was an effective salvage regimen in heavily pretreated patients with chemoresistant or relapsed GTN. To evaluate whether FAEV chemotherapy is superior to other salvage chemotherapy regimens, a multi-institutional randomized trial is needed to select the most appropriate chemotherapy regimen in patients with chemoresistant or relapsed GTN.
